Podcasts about Alcon

Trump menace, Trump recule, Trump remenace… et pendant ce temps, les marchés essaient de garder leur calme. Cette semaine, on débriefe le chaos organisé made in Donald, la fameuse stratégie TACO (Trump Always Chickens Out), les chiffres de l'inflation PCE, les résultats de Nvidia, et les prédictions flippantes de Jamie Dimon sur l'obligataire.

In this episode of UNSCRIPTED, host Sarah Nicastro sits down with Kenny Brown, Senior Director of Global Surgical and Vision Care Franchise Business Technology at Alcon, to explore the company's comprehensive service overhaul. Learn how Alcon partnered with Disney to refresh its take on the customer experience, built a foundation for global standardization, and is now leveraging generative AI to take service delivery to the next level. This conversation offers practical insights on managing change, engaging employees, and creating lasting business impact across a global organization.

Send us a textIn this episode of the Life Science Success Podcast my guest is Thomas Ruggia, the President and CEO of Samsara Vision, a specialty medical device company focused on developing innovative implantable ophthalmic technologies to improve vision for individuals with untreatable retinal disorders. With extensive experience in ophthalmology from his previous roles at Johnson & Johnson and Alcon, Thomas brings a wealth of knowledge and passion to Samsara Vision's mission of rejuvenating eyesight and helping people reconnect with the world around them.00:00 Introduction to Life Science Success Podcast00:34 Meet Thomas Ruggia: CEO of Samsara Vision01:38 Thomas Ruggia's Journey into the Medical Device Industry03:14 Career Highlights: Alcon and Johnson & Johnson11:49 Samsara Vision's Flagship Product: Seeing IMT17:31 Future of Ophthalmic Devices and Treatments27:26 Personal Insights and Leadership Advice31:08 Global Perspective and Concerns34:46 Excitement for Future Technologies40:19 Conclusion and Farewell

White House economic adviser Hassett said the administration has more than 20-25 deals on the table with deals close to being finalised and when President Trump returns, he will announce the next deal, according to a Fox interview.US President Trump said his relationship with China is good and he could see himself dealing with Chinese President Xi on a deal, according to a Fox News interview.US President Trump said the market will go higher and it is amazing what a climbing market will do.APAC stocks traded somewhat mixed but with the region predominantly in the green following the momentum from the constructive performance on Wall St.European equity futures indicate a lower cash market open with Euro Stoxx 50 futures down 0.2% after the cash market closed with gains of 0.4% on Tuesday.Looking ahead, highlights include German/Spanish CPI (Final), OPEC MOMR, Speakers include BoE's Breeden, ECB's Cipollone, Fed's Waller, Jefferson & Daly, Supply from UK & Germany, Earnings from Cisco Systems, CoreWeave, Alcon, Imperial Brands, Burberry, Daimler Truck, Brenntag & Por.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

In this special episode, Jackye Clayton joins Bill Banham to preview UNLEASH America 2025, an event she describes as offering key solutions to the most pressing workplace challenges.UNLEASH AMERICA Conference & Exhibition, one of the fastest-growing HR event in the world, is a place where global HR Leaders come to do business and discover inspirational stories that change ways organizations think about HR and innovation.Jackye's passion for improving work experiences shines through as she shares her excitement for this Las Vegas conference happening May 6-8 at Caesars Palace. "What keeps me up at night really is the state of the world of work," she explains. "We all need jobs, we're all trying to make a living, we all want to take care of our family, and so I really want it to not suck." This refreshingly honest perspective frames her anticipation for the event's three major focus areas.First, the conference tackles AI in HR - examining both its promise and pitfalls. Jackye highlights Dr. Joy Buolamwini, founder of the Algorithmic Justice League, who will address algorithmic bias and preventing inequality in AI strategies. Second, human-centered leadership takes center stage, ensuring "that the technology serves humanity, not that we are serving the technology." Finally, inclusive talent strategies return to prominence with panels like "DEI at a Crossroads" featuring representatives from Alcon and the Canadian Olympic Committee. Additional highlights include a panel on redefining talent acquisition with remote work, featuring Active, Atlassian, and Toshiba.The massive UNLEASH expo hall will showcase cutting-edge HR technologies and innovative startups that represent "the future of HR and talent acquisition." If you're attending Unleash America, Jackye invites you to connect with her there—she's eager to meet fellow HR professionals passionate about transforming the world of work. Support the showFeature Your Brand on the HRchat PodcastThe HRchat show has had 100,000s of downloads and is frequently listed as one of the most popular global podcasts for HR pros, Talent execs and leaders. It is ranked in the top ten in the world based on traffic, social media followers, domain authority & freshness. The podcast is also ranked as the Best Canadian HR Podcast by FeedSpot and one of the top 10% most popular shows by Listen Score. Want to share the story of how your business is helping to shape the world of work? We offer sponsored episodes, audio adverts, email campaigns, and a host of other options. Check out packages here. Follow us on LinkedIn Subscribe to our newsletter Check out our in-person events

In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he's now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:The evolution of his career from medical device sales to surgical commercialization and C-suite leadership.Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass.The market opportunity for post-MiGs patients and how IanTrek's platform opens new treatment options without burning surgical real estate.Insights into IanTrek's growing bio-interventional pipeline and what's ahead in 2025 and beyond.Whether you're a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed. Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.In this episode, you'll learn:Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.The company's go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.What makes presbyopia such a powerful entry point into the broader continuum of vision care.With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.Don't miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what's next in ophthalmic innovation!

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., has revealed intentions to reduce 10,000 positions and restructure departments. The appointment of vaccine critic David Geier to investigate vaccine safety within the CDC has also been announced. Soleno has recently obtained FDA approval for a medication designed to address hyperphagia in Prader-Willi syndrome patients. Meanwhile, Johnson & Johnson's combination therapy for lung cancer has displayed encouraging outcomes. A power struggle at Aurion has resulted in Alcon taking control, amidst allegations of impeding Aurion's IPO plans. Opportunities in the biopharma industry are available at the United States Pharmacopeia, alongside updates on biopharma layoffs and industry advancements. That's all for today's episode. Stay tuned for more essential news from the world of Pharma and Biotech. Thank you for listening.

Timestamps:5:55 - An Icelandic company headquartered in Switzerland16:29 - Fundraising for long development cycles19:00 - Doing the only Swiss IPO in 202324:23 - Splitting your focus to sell 3 products at once28:39 - Advantages and disadvantages of being publicly listedThis episode was produced in collaboration with startup days, taking place this year on May 14th 2025. Click ⁠here⁠ to purchase your ticket.Click here to check out our free Founders Agreement masterclass, with Melanie Gabriel from Yokoy, Christof Roduner from Scandit, and Viviana Gropengiesser from Talent Kick.About Riad Sherif:Riad Sherif is the CEO at Oculis, a company focused on the development of topical treatments for ophthalmic diseases in the back and front of the eye. He holds a MSc in Medical Management from the ESCP Business School and worked at companies like Sanofi, Novartis and Alcon before joining Oculis as CEO in 2017.Oculis' pipeline includes a topical eye drop candidate for diabetic macular edema and for the treatment of inflammation and pain following cataract surgery. It also includes a candidate for dry eye disease and for non-infectious anterior uveitis, and a candidate for acute optic neuritis. The company's origins are in Iceland, where the OPTIREACH® solubilizing formulation technology was developed by two Icelandic co-founders, Professors Einar Stefánsson and Thorsteinn Loftsson, to enable eye drops to reach the back of the eye. Nowadays Oculis is headquartered in Switzerland, with operations in the US and Iceland. Oculis has raised a total of $284.6M in funding over 13 rounds, and went public in 2023 (the only Swiss IPO of that year) before their product was even live. It is currently at stage 3 of clinical trials.The cover portrait was edited by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.smartportrait.io⁠⁠⁠⁠⁠⁠⁠‍Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

This week, we revisit our interview with Keith Grossman. He currently serves as Chairman of Nevro Corp. (NVRO), Vice-Chairman of Alcon, Inc. (ALC), and Lead Director of Outset Medical, Inc. (OM). Previously, Keith was the CEO and President of Nevro. Keith has over 40 years of experience in the medical device field. He served most recently, and for the second time, as the President, Chief Executive Officer, and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical.   Before Thoratec, he served as President, Chief Executive Officer, and director of Conceptus, a women's health medical device company, leading up to its sale to Bayer Healthcare. Before Conceptus, Keith served as managing director of TPG (Texas Pacific Group), a private equity firm, and was a member of its healthcare investment team. Prior to TPG, Keith served as Thoratec's President, Chief Executive Officer, and director for the first ten years of its growth as a commercial company.  Keith was chronicled in the book “Executive Intelligence: What All Great Leaders Have”, was named among the “Business Leaders to Watch” and the “40 Under 40” lists in the Bay Area and was awarded the Lifetime Achievement Award by his Medical Device CEO peers. Keith received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. J&J is currently involved in a legal battle with Samsung Bioepis, alleging unlawful sublicensing of a Stelara biosimilar. Meanwhile, Takeda has made a significant investment in a new BridGene partnership aimed at targeting undruggable targets. In other news, Regeneron has made strides in developing a gene therapy that can restore hearing in patients with rare genetic deafness. However, Deerfield Management claims that Alcon is hindering Aurion Biotech's IPO progress. Additionally, Trilink is offering mRNA designs that ensure reliable performance across various applications. There have also been reports of compounders suing the FDA, Reperio Therapeutics downsizing their staff, and discussions on how to support small molecule innovations in the industry. And if you missed it, recent developments include Trump threatening big pharma with tariffs, the FDA rehiring scientists, and advancements in pain treatment, RNA editing, and gene therapies being highlighted. Opportunities in neuroscience sales, regulatory affairs, and marketing are currently available for those interested. Thank you for tuning in to Pharma and Biotech Daily for the latest updates in the industry.

Blurb: In this episode of the ESCRS IME Leadership Opinion Series on the Digital Operating Room (DOR), Dr. Norbert Pesztenlehrer shares his journey to adopting a DOR, offering a detailed look at his clinic's setup, the challenges he faced, the roadblocks he overcame, and the benefits he has gained. He also provides valuable advice for surgeons considering a digital transition. Don't miss this insightful episode – listen now and explore the full series!   Independent medical education supported by Alcon and Zeiss.

Blurb: In this episode of the ESCRS IME Leadership Opinion Series on the Digital Operating Room (DOR), Dr. Karen Glandorf discusses the challenges of traditional workflows, shares insights into her DOR setup, and explains how it has improved her daily practice. She also explores the future of the DOR and the transformative role of AI in surgical innovation. Plus, Dr. Glandorf offers valuable advice for surgeons looking to integrate a DOR into their practice. Don't miss this insightful episode – listen now and explore the full series!   Independent medical education supported by Alcon and Zeiss.

Damien Bradley of Team Legacy UK is entered to run the 2025 Pikes Peak Hill Climb. He will be piloting a 1992 Legacy that has been setting hill climb records in the UK.Damien has been working with Roger Clark Motorsports, AET Turbos, and Alcon brakes and many others through the years as he developed and improved his Hill Climb Monster, and we had the opportunity to chat with him about competing in Time Attack, Hill Climbs across the UK, and what it means to him to be able to compete in the 2025 Pikes Peak Hill Climb.Be sure to follow Team Legacy UK on Instagram and Youtube for all the latest as they get ready to Race to the Clouds in just a few months!https://www.youtube.com/@UCXp2U31MvKNalY7a8zy3hvg https://www.instagram.com/teamlegacyuk/https://www.teamlegacyuk.co.uk/Thanks for watching and Stay Tuned!

En el Foro de la Inversión de Capital Intereconomía, Pilar Bravo, Directora de Desarrollo de Negocio de Finaccess Value, presentó la estrategia de inversión del fondo Finaccess Compromiso Social Europa. Este fondo de renta variable europea combina rentabilidad financiera con un impacto social positivo, invirtiendo en compañías que contribuyen a retos como la salud, la educación, la inclusión financiera y el acceso a la vivienda. Bravo explicó que la selección de valores sigue un riguroso filtro que evalúa tanto el rendimiento financiero como el impacto social de las empresas. La cartera está compuesta por 40 compañías diversificadas en sectores como el industrial, financiero, salud y consumo básico, con Francia, Países Bajos, Alemania y Reino Unido como principales mercados. Empresas como Alcon, Novo Nordisk o Mapfre destacan por su contribución a la mejora de la calidad de vida. Con dos años de trayectoria, el fondo cerró 2024 con una rentabilidad del 7,47% .La estrategia de gestión activa permite adaptarse a la incertidumbre del mercado, manteniendo el compromiso con la inversión sostenible

Darryl Glover Jr., OD; Britt E. Gustafson, OD; and Selina R. McGee, OD, FAAO, discuss contact lenses as an integral pillar of their practice success. They review how technology, such as Alcon's WaterInnovationsTM portfolio, helps them differentiate their practice from competitors by customizing fit and comfort to each patient. They also explain how to present this new technology and educate patients about their options. US-DT1-2400098 Sponsored by Alcon 

Witajcie w 965. odcinku podcastu BSS bez tajemnic! Tym razem poruszamy temat, który dotyczy nas wszystkich – zdrowia naszych oczu. Gośćmi tego odcinka są eksperci z firmy Alcon: Paulina Duda-Tomczyk, Senior Brand Manager, oraz Tomasz Suliński, Specjalista ochrony wzroku z działu szkoleń. Wspólnie omawiamy, jak ważne jest regularne badanie wzroku i dlaczego firmy coraz częściej organizują takie akcje dla swoich pracowników.Czy wiesz, że nasze oczy to jeden z najważniejszych, a jednocześnie najbardziej obciążonych narządów? W dzisiejszych czasach spędzamy godziny przed ekranami komputerów i smartfonów, co może prowadzić do wielu problemów ze wzrokiem, takich jak zmęczenie oczu, suchość czy pogorszenie widzenia. Paulina i Tomasz opowiadają o tym, jakie są najczęstsze wyzwania związane z ochroną wzroku i jak wpływają one na codzienne funkcjonowanie – zarówno w życiu zawodowym, jak i prywatnym.W rozmowie dowiesz się także:Jakie korzyści przynosi firmie organizowanie badań wzroku dla pracowników?Dlaczego regularne badanie wzroku powinno stać się nawykiem każdego z nas?Skąd wziął się pomysł na akcję badania wzroku wśród pracowników firm?Jak wygląda organizacja takiego wydarzenia i co się na nie składa?To odcinek pełen cennych informacji, który uświadamia, że troska o zdrowie oczu to nie tylko kwestia indywidualna, ale też istotny element budowania zdrowego środowiska pracy.  Kluczowe punkty z rozmowy: ·         Regularne badania wzroku są kluczowe dla utrzymania jego zdrowia i komfortu, szczególnie dla pracowników biurowych.·         Wada wzroku nie jest chorobą i można ją skutecznie korygować za pomocą odpowiednio dobranych okularów lub soczewek kontaktowych.·         Programy zdrowotne oferowane przez firmy, takie jak badania wzroku, zwiększają komfort pracowników i mogą poprawić ich wydajność oraz satysfakcję z pracy.  Jeśli chcesz zorganizować badanie wzroku w Twojej firmie, to skontaktuj się z Partnerem Alcon – firmą Pro Progressio pisząc na adres biuro@proprogressio.pl. Dostaniesz więcej informacji oraz bezpośredni kontakt z osobami odpowiadającymi za badania wzroku.  Linki:Alcon – https://www.pl.alcon.com/plPaulina Duda-Tomczyk na Linkedin – https://www.linkedin.com/in/paulina-duda-tomczyk-4721b386/Tomasz Suliński na Linkedin – https://www.linkedin.com/in/tomasz-suli%C5%84ski-10661764/Porozmawiaj o tym podcaście ze sztuczną inteligencją – https://bbs-bez-tajemnic.onpodcastai.com/episodes/fvlKzSnh8aI/chat  ****************************  Partnerem podcastu BSS bez tajemnic jest Selgros24.pl - https://selgros24.pl/pl/  ****************************  Nazywam się Wiktor Doktór i na co dzień prowadzę Klub Pro Progressio https://klub.proprogressio.pl/pl – to społeczność wielu firm prywatnych i organizacji sektora publicznego, którym zależy na rozwoju relacji biznesowych w modelu B2B. W podcaście BSS bez tajemnic poza odcinkami solowymi, zamieszczam rozmowy z ekspertami i specjalistami z różnych dziedzin przedsiębiorczości.Zapraszam na moje media społecznościowe i do bezpośredniego kontaktu:YouTube - https://www.youtube.com/@wiktordoktorFacebook - https://www.facebook.com/wiktor.doktorLinkedIn - https://www.linkedin.com/in/wiktordoktor/Moja strona internetowa - https://wiktordoktor.pl/Możesz też do mnie napisać. Mój adres email to - kontakt(@)wiktordoktor.pl  ****************************Patronami Podcastu “BSS bez tajemnic” są:Marzena Sawicka https://www.linkedin.com/in/marzena-sawicka-a9644a23/Przemysław Sławiński https://www.linkedin.com/in/przemys%C5%82aw-s%C5%82awi%C5%84ski-155a4426/Damian Ruciński - https://www.linkedin.com/in/damian-rucinski/Szymon Kryczka https://www.linkedin.com/in/szymonkryczka/Grzegorz Ludwin https://www.linkedin.com/in/gludwin/ Adam Furmańczuk https://www.linkedin.com/in/adam-agilino/Wspaniali ludzie, dzięki którym pojawiają się kolejne odcinki tego podcastu. Dołącz do grona Patronów podcastu na:Patronite - https://patronite.pl/wiktordoktorPatreon - https://www.patreon.com/wiktordoktorBuy me a coffee - https://www.buymeacoffee.com/wiktordoktorZrzutka.pl - https://zrzutka.pl/j8kvarBecome a supporter of this podcast: https://www.spreaker.com/podcast/bss-bez-tajemnic--4069078/support.

Drs. Kat Talcott, Akshay Thomas, and Sarwar Zahid join the podcast for a journal club discussion covering three recent articles in major ophthalmology journals.Pneumatic Retinopexy IRIS Registry (https://www.ophthalmologyretina.org/article/S2468-6530(24)00526-8/fulltext)Macular Perfusion in Stable PDR (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2826881)Female Speaker Introductions (https://www.ajo.com/article/S0002-9394(24)00522-1/fulltext)Relevant Financial Disclosures: Dr. Sridhar has consulted for Alcon.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this recap of 2024, Patrick and Jaime sit down to review highlights of the year, the wrapping of Blade Runner 2099, notable discussions and more. We have a lot in store for 2025. With what we hope will be a fantastic new live action series from Alcon and Amazon, there will be a lot to discuss in the coming months. Thank you for listening to the show and supporting us over the years. Happy New Year!   // For more on this and our other projects, please visit www.bladerunnerpodcast.com  // If you'd like to join the conversation, find us on our closed Facebook group: Fields of Calantha. // To support the show, please consider visiting www.bladerunnerpodcast.com/support. We've got some great perks available! // And as always, please consider rating, reviewing, and sharing this show. We can't tell you how much your support means to us, but we can hopefully show you by continuing to provide better, more ambitious, and more dynamic content for years to come.

Among the learnings that Dev Ahuja has gleaned from his three-decade-long, globe-hopping finance career, perhaps none has delivered a more enduring instruction than that which followed his very first hop.By his own account, after Ahuja had reached the summit of Novartis's finance executive ranks in India, the drug giant invited him to occupy an office at its Basel, Switzerland, headquarters. Here, Ahuja was promised, he would be able to apply his flourishing financial acumen on a more global scale. “I thought that I knew what it took—I came with a lot of confidence rather than in a mode of humbleness and wanting to learn,” comments Ahuja, who let us know that his first years at headquarters did not always go as planned.Ahuja reports: “The Swiss don't mince words."Confronted with his shortcomings, Ahuja set out to get things back on track—beginning with a hefty dose of self-scrutiny. “I had done a miserable job because I really had not made the effort to build relationships and take the time and make the effort to understand the cultural nuances,” remarks Ahuja, whose track change paid off with a Swiss stint in the roles of group controller and head of Basel's finance operations that stretched to 5 years.Still, Ahuja's Swiss experiences would prove to grow even more valuable in the years ahead, as he would come to occupy the CFO offices of Novartis Korea (3 years) and Novartis Japan (2 years).“Novartis was very active when it came to developing people across geographies, but my case—where I would end up living in five different countries—was not very normal,” observes Ahuja, whose fifth nation became the U.S. after the drugmaker's $46 billion acquisition of Alcon opened the door to a number of opportunities for him.Announced in 2010, the Alcon deal was to present post-merger integration challenges that in part led Novartis to relocate Ahuja from Korea to Japan, where the Alcon integration tasks were more pressing.“We accomplished a lot in Japan in a short period of time, and it seems that Alcon U.S.—which was twice the size of Alcon Japan—was in need of some of what we had learned,” recalls Ahuja, who tells us that at the time, a son had recently relocated to the U.S. for studies.With little delay, it seems, Ahuja was headed to Fort Worth, Texas, to serve as CFO North America for the drug giant's Alcon division—a business that years later would nab business headlines when Novartis opted to spin it off.According to Ahuja, he has been able to apply his Swiss “lessons” at each career move, including his change when he departed from Novartis in 2016 to accept the CFO position at aluminum products giant Novelis.It seems that regardless of whether a move has involved geographies or industries, Ahuja has been able to apply the benefits of his time in Switzerland.Says Ahuja: “When you fail, you must make up your mind to take every lesson from that failure and act on it.” –Jack Sweeney

Mickael Dang is co-founder of Synakis, a biotech startup developing groundbreaking technology for the treatment of retinal detachment. Still in startup mode, the company is part of UTEST, the University of Toronto's Early Stage Technology Program, which helps deep tech entrepreneurs go from lab to market. Mickael and Wendy connected at the Redefining Early Stage of Investment (RESI) Conference in Boston, where Synakis was among the highest-scoring companies in the Innovator's Pitch Challenge. (The RESI conference is hosted by Life Science Nation and Wendy recently interviewed Dennis Ford, founder and CEO of Life Sciences Nation, which specializes in fundraising for life sciences companies.)  Mickael's journey is fascinating. When he arrived in Canada from France six years ago, he could barely string together an English sentence. Today, we find him at the intersection of scientific innovation, entrepreneurship, and global market expansion, having started Synakis while earning a PhD and serving as President of the Student and Young Investigator Section (SYIS) of TERMIS (Tissue Engineering and Regenerative Medicine Society). He is also multilingual; he speaks French, English, and some Mandarin.  “The PhD is the same concept as being an entrepreneur,” he says. “You need to be very self-driven, very independent as well. You have to come up with your own experiment and come up with the next predicted results. I had this entrepreneurial mindset from the get-go and wanted to do a PhD for purpose, to really get the company out there."  Incubated in the laboratory of renowned biomedical engineering professor Dr. Molly Shoichet, Synakis is developing a revolutionary hydrogel-based technology called SNK125. This innovation promises to transform the recovery process for patients suffering from retinal detachment, a serious condition that requires immediate surgical intervention to prevent permanent vision loss.  Current treatments for retinal detachment involve using silicon oil or heavy gases to push the detached retina back into place. While these methods work, they come with significant drawbacks. Patients experience blurry vision during recovery and must maintain exhausting, face-down posturing for hours, sometimes for months. In addition, the materials used aren't biodegradable, requiring a second surgery for removal. Synakis's hydrogel technology eliminates all of these challenges, while reducing recovery time from months to just days.    The Global Path to Market  Equally interesting is the company's approach to global market entry. Based in Canada, the company has already laid the groundwork for international expansion; in 2019, Mickael proactively filed patents across multiple territories, including Europe, Australia, Canada, and China, to ensure protection of its intellectual property globally. And rather than attempting to tackle multiple markets simultaneously, Synakis will initially focus on North America before expanding to Europe and China. This staged approach allows them to establish a strong foundation in their home market while building the partnerships and relationships required for international expansion.  Throughout, Mickael and his team have been actively seeking partnerships with established industry giants like Alcon or Bausch & Lomb. There are high costs associated with clinical trials these companies – companies that "own the entire market," according to Mickael – have the expertise and distribution networks necessary for successful commercialization.    Funding the Future  Synakis is concurrently seeking seed investment and focusing on several critical milestones: Good Manufacturing Practices (GMP) setup, FDA regulatory filing, and preparation for clinical trials. While its primary focus is on North American investors for practical reasons like time zone alignment and ease of communication, they're keeping their options open for international investment, particularly in regions like China, which possess significant market opportunity. Mickael has constructed a targeted and strategic approach to investor outreach. At the RESI conference, for example, he prioritized meetings with specialized investors like ExSight Ventures, who focus specifically on ophthalmology. These are the meaningful conversations with investors that will ask the hard questions and offer solutions.    Looking Ahead  Synakis is currently preparing for its next phase of growth. Plans include moving out of the university incubator, creating new jobs in Toronto, and expanding their product pipeline beyond retinal detachment treatments to include drug delivery solutions for other eye conditions.  Mickael's key takeaways from his Synakis journey are relevant for any company planning international expansion:  Strategic IP Protection: Early patent filing in target markets will protect future opportunities.  Staged Market Entry: Starting with familiar markets before expanding globally can help manage resources and risk effectively.  Strategic Partnerships: Recognizing when to partner with established players can accelerate market entry and provide access to crucial resources.  Targeted Investor Outreach: Focusing on investors who understand your industry can lead to more productive relationships.  Cultural Adaptability: Language skills and cultural understanding are invaluable assets in building a global business.  Going from lab to market can be, as Mickael says it in French, a "casse-tête" (a “head-breaker”), but the right approach, persistence, and strategic thinking can ultimately turn scientific innovation into global market success. Listen to the full episode to hear more about Synakis's journey from university lab to potential global market player, plus more real-world advice for expanding internationally.    Links: LinkedIn: https://www.linkedin.com/in/mickael-dang/  Website: https://www.linkedin.com/company/synakis/  https://utest.to/  https://termis.org/index.php?q=termis-syis-am     

► Get a free share! This show is sponsored by Trading 212! To get free fractional shares worth up to 100 EUR / GBP, you can open an account with Trading 212 through this link https://www.trading212.com/Jdsfj/FTSE. Terms apply. When investing, your capital is at risk and you may get back less than invested. Past performance doesn't guarantee future results. ► Get 15% OFF Finchat.io: Huge thanks to our sponsor, FinChat.io, the best investing toolkit we've discovered! Get 15% off your subscription with code below and unlock powerful tools to analyze stocks, discover hidden gems, and build income streams. Check them out at FinChat.io! https://finchat.io/playingftse/?lmref=iQl2VQ ► Episode Notes: What links Sartorius, Novo Nordisk, and Svenska Handeslbanken? Find out on this week's PlayingFTSE Show! It's a very unusual week this week on the podcast. Both the FTSE 100 and the S&P 500 are down BUT THE STEVES ARE NOT – THEY'VE BOTH OUTEPERFORMED.  Steve W has been looking at big tech for this week's quick news roundup. Google has a quantum computing chip (good luck with that) and Amazon is getting into car sales (good luck with that, too.) In Steve D's news, Adobe beat earnings but the stock fell and Vanguard has announced some changes in its pricing structure. One is much more impressive than the other, but is Steve about to do anything? The main bit of this week's show, though, is our Eurobox. Following last week's UK edition, we're having a go at 30 stocks (15 each) from Europe (and Switzerland because otherwise it's too hard for Steve W).  ASML, Adyen, and Dassault kick off Steve D's contribution. Two of those will be very familiar to regular listeners, but the third is an impressive French software company we've not discussed before. Differentiated consumer products have been a theme for Steve W this year. And he's got his eye on Inditex (fashion), Adidas (apparel), and Essilorluxottica (sunglasses) as stocks to consider buying. Steve D's healthcare trio are Alcon, Argenx, and Lonzo. All have strong competitive positions and impressive growth prospects, but they cover different parts of the pharmaceutical industry. One thing Europe does well is luxury goods and Steve W is on the case. Ferrari is one of the most recognisable brands in the world, but he's also adding Porsche and Pernod Ricard to the mix.  A semiconductor equipment company, a consulting firm, and an infrastructure specialist make up Steve D's industrials. They're all based in Europe but each one has a global reach.  Steve W's also on the industrials. He's sticking to his preferred theme of aircraft building with Airbus and Safran, but there's also a medical equipment company in there, in the form of Carl Zeiss Meditec. When Steve D thinks of tech, he thinks of Spain. And joining Amadeus IT in this part of the Eurobox is Dutch stock exchange Euronext and private equity operation Groupe Bruxelles Lambert.  Companies with a cost advantage really get Steve W going from an investment perspective. And with Ryanair, Basic Fit, and Dino Polska, two out of three isn't that bad… Nemetschek, bioMérieux, and Redcare Pharmacy are stocks that almost nobody has heard of. But Steve D thinks a closer investigation explains why they're worth their place in the group.  Steve W's taken a look at Novo Nordisk, Sartorius, and Svenska Handelsbanken. Strong companies all three, but good luck finding a theme that ties them together.  And that's the lot for the Eurobox. Steve D's carefully selected his and Steve W named every stock he could think of – but neither of them listed LVMH! All that's left is to name our top two individual choices and a joint favourite for additional weight. These are Adyen, Dassault, Ryanair, and Svenska Handelsbanken, and the joint choice is Novo Nordisk. Only on this week's PlayingFTSE Podcast! ► Support the show: Appreciate the show and want to offer your support? You could always buy us a coffee at: https://ko-fi.com/playingftse (All proceeds reinvested into the show and not to coffee!) There are many ways to help support the show, liking, commenting and sharing our episodes with friends! You can also check out our clothing merch store: https://playingftse.teemill.com/ We get a small cut of anything you buy which will be reinvested back into the show... ► Timestamps: 0:00 INTRO & OUR WEEKS 06:38 GOOGLES QUANTUM LEAP 13:20 ADOBE EARNINGS 17:08 AMAZON CARS? 22:18 VANGUARD NEWS 27:14 EUROBOX INTRO 28:29 EUROBOX SET ONE! 35:22 EUROBOX SET TWO! 42:11  EUROBOX SET THREE! 48:31 EUROBOX SET FOUR! 56:03 EUROBOX SET FIVE! 1:02:59 BEST FIVE! ► Show Notes: What's been going on in the financial world and why should anyone care? Find out as we dive into the latest news and try to figure out what any of it means. We talk about stocks, markets, politics, and loads of other things in a way that's accessible, light-hearted and (we hope) entertaining. For the people who know nothing, by the people who know even less. Enjoy ► Wanna get in contact? Got a question for us? Drop it in the comments below or reach out to us on Twitter: https://twitter.com/playingftseshow Or on Instagram: https://www.instagram.com/playing_ftse/ ► Enquiries: Please email - playingftsepodcast@gmail(dot)com ► Disclaimer: This information is for entertainment purposes only and does not constitute financial advice. Always consult with a qualified financial professional before making any investment decisions.

If you have a WRX or and STI, and you have taken it to the track a few times, or have tuned it up to make more power, you may be at the point where you want or need to upgrade your brakes. There are a number of common upgrades, such as the Subaru 4-Pot and 2-Pot calipers from the 06-07 WRX, or the STI Brembos. And ever since the STI got the larger Brembo 6-piston calipers, those are becoming a more common upgrade as well for both WRXs and STIs. So when would you want to go with a set of OEM Plus calipers, and when would you want to look at a motorsport brake option from AP Racing or Alcon? We go through all of these options in this video and talk about the pros and cons of each. If you are interested in any of these kits, or would like to get more information about them, here are links to all of the brake kits discussed on our site: Subaru 4-Pot and 2-Pots https://www.flatironstuning.com/subaru-4-pot-2-pot-brake-upgrade STI Black Brembo Calipers https://www.flatironstuning.com/subaru-oem-black-brembo-calipers-front-pair-08-17-sti https://www.flatironstuning.com/brembo-rr-bk AP Racing 325mm Brake Kit https://www.flatironstuning.com/essex-designed-ap-racing-comp-big-brake-kit-04-17-sti AP Racing Rally Brake Kit https://www.flatironstuning.com/ap-racing-by-essex-rally-comp-brake-kit-front-cp8350-299mm-93-21-sti-wrx-2-5rs WRX TR Brembo 6-Piston Brake Kits https://www.flatironstuning.com/catalogsearch/result/?q=Flatirons%20Tunign%20WRX%20TR Roger Clark Alcon Brake Kits https://www.flatironstuning.com/rcm2836 https://www.flatironstuning.com/rcm2960 https://www.flatironstuning.com/rcm2837 AP Racing Radi-Cal Brake Kit for the STI https://www.flatironstuning.com/13-01-10067 Thanks for watching and Stay Tuned!

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die Fettweg-Enttäuschung bei Amgen, süße Gewinne für JM Smucker und klingelnde Kassen bei Novo Nordisk und Eli Lilly. Außerdem geht es um Bayer, Cooper Companies, Johnson&Johnson, Alcon, Crowdstrike, Workday, Dell, Rigetti, Quantum Computing, D-Wave Quantum, Coinbase, General Motors, Stellantis, Ford, Assa Abloy, Signify, Volkswagen, Mercedes, BMW, Legrand, Schneider Electric, Siemens, Nibe, SKF, NKT, Atlas Copco, Volvo, Metso, Daimler Trucks und ishares S&P Small Cap 600 (WKN A0Q1YY), Xtrackers Russel 2000 (WKN: A1XEJT). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Send us a textIn this episode, Ryan shares his inspiring journey into engineering, overcoming challenges through relentless persistence, and developing daily habits to drive personal and professional growth. He discusses the importance of finding your purpose, the power of rapid prototyping, and strategies for accelerating engineering progress.Main Topics Covered:Ryan's background and how he discovered his passion for engineeringThe role of hard work, persistence, and a growth mindset in achieving successDeveloping daily routines and habits to support personal and professional developmentNavigating complex engineering projects and building confidence through problem-solvingAdvice for young engineers on finding their niche and accelerating their careersBooks discussed during the episode:Think and Grow RichRich Dad, Poor DadHow to Win Friends and Influence PeopleCrucial ConversationsFailing ForwardAbout the guest: Ryian Williams is an energetic and ambitious engineer who has built an impressive career in product design and development, particularly in the medical device space. With over six years of experience at Alcon, a global leader in eye care, Ryian currently serves as a Senior Engineer in Technology Transfer. His role involves bridging the gap between design and manufacturing, ensuring that innovative medical products are successfully brought to market. Ryian's passion for engineering is matched by his dedication to continuous learning and self-improvement, which has also led him to become a TEDx speaker, author, and content creator. He holds a Master's degree in Mechanical Engineering from the University of Texas at Arlington and has been involved in a wide range of engineering roles, from CAD draftsman to product design and R&D engineering.Links:Ryian Williams - LinkedInAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Listen to Octane's Medical Innovation Forum coverage. In this episode, Adam Torres interviews Neda Dadashzadeh, Principal Optical Engineer at Alcon. Explore Octane's Medical Innovation Forum. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia

Plus Can AI Make You A Narcissist? Like this? Get AIDAILY, delivered to your inbox, every weekday. Subscribe to our newsletter at https://aidaily.us Using AI to Become a Better Version of Yourself Mathias Sundin shares his experience of using AI not just for efficiency but personal growth. With WALL-Y, an AI news writer, he cuts production time by 80-90%, freeing up time for creative tasks. AI also enhances skills Sundin lacks, like music production, and strengthens his writing through personalized AI tools. His AI editor, tailored to his personality, refines ideas and builds on his strengths. Sundin envisions a future where AI becomes an extension of our minds, accelerating both personal and professional aptitudes, helping individuals achieve their goals and dreams AI-Driven Research Tool Sparks Narcissism Concerns Google's NotebookLM, designed as an AI-powered research assistant, is raising concerns about unintended psychological effects. While it can sift through documents and even generate playful podcasts from users' text histories, journalist Jacob Aron warns it may encourage narcissism and nostalgia. The tool offers more than research assistance—potentially creating a “too nice” AI companion that boosts egos and tempts users to dwell on an idealized view of themselves.  News Corp Sues Perplexity AI Over Copyright Infringement Dow Jones and the New York Post have filed a lawsuit against Perplexity AI, accusing it of large-scale copyright infringement. The complaint alleges that Perplexity unlawfully reproduces and repurposes original content, diverting traffic and revenue from news publishers. The lawsuit seeks damages of up to $150,000 per infringement. News Corp CEO Robert Thomson criticized Perplexity's practices, calling them a “content kleptocracy.” Alcon Entertainment Sues Elon Musk and Tesla Over 'Blade Runner 2049' Imagery The producers of Blade Runner 2049 filed a lawsuit against Elon Musk, Tesla, and Warner Bros., claiming the unauthorized use of film imagery to promote Tesla's Cybercab. Alcon alleges Musk fed film visuals into AI tools despite being denied permission. The lawsuit also highlights Alcon's opposition to Musk's controversial views, aiming to distance the company from his brand. Tesla's stock took a hit following the Cybercab launch, criticized for lacking key details. This legal action adds to ongoing tensions between Hollywood creatives and Musk's companies. AI Reshapes Real Estate Management AI is revolutionizing real estate, transforming how office spaces are managed amid shifting market trends. Tools like MIT spinout Butlr's heat-sensing technology optimize space usage, while predictive AI streamlines maintenance and lease abstraction. AI also forecasts market trends, aiding hybrid office layouts and social housing projects. Despite privacy concerns, adoption is growing as AI integrates seamlessly into operations, enabling companies to reduce costs and increase efficiency in the evolving real estate landscape.

Tesla-baas Elon Musk wordt aangeklaagd door Warner Bros. Discovery en Alcon, de rechtenhouders achter de film Blade Runner 2049. Joe van Burik legt het uit in deze Tech Update. Tesla en Musk zijn aangeklaagd door Warner Bros en Alcon wegens een afbeelding bij de onthulling van de Cybercab, de geanticipeerde robotaxi van Tesla. Daarbij gebruikte het merk namelijk AI om de promo-afbeelding te genereren, waarbij volgens de rechterhouders inbreuk is gemaakt op het copyright op de film Blade Runner 2049. Kort vóór het event ontvingen Warner Bros en Alcon namelijk nog het verzoek om een beeldmerk van die franchise te mogen gebruiken, maar dat werd niet toegekend. Verder in deze Tech Update: Meta gaat meer gezichtsherkenning inzetten, onder meer om nep-advertenties met beelden van bekende mensen te bestrijden, maar ook op het opnieuw toegang krijgen tot Facebook- en Instagram-accounts mogelijk te maken AI-zoektool Perplexity wordt aangeklaagd door een stel grote kranten, namelijk The Wall Street Journal en de New York Post van News Corp See omnystudio.com/listener for privacy information.

In this ESCRS IME podcast on the Digital Operating Room (DOR), Drs. Kjell Gunnar Gundersen and Wolfgang Mayer explore the evolving landscape of the DOR, discussing its definition and the transformative impact of digital technologies on their daily surgical practices. They highlight the benefits of integrating digital operating rooms, emphasizing improved efficiency and workflow, the role of data systems integration in enhancing patient outcomes, and the potential future of remote consultations and surgeries. To hear more about this topic, make sure to listen the other two podcasts in this series. Independent medical education supported by Alcon and Zeiss.

In this ESCRS IME podcast on the Digital Operating Room (DOR), Drs. Wolfgang Mayer and Kjell Gunnar Gundersen discuss how 3D visual operating systems and augmented reality enhance surgeon ergonomics, potentially reducing long-term health issues for cataract surgeons while improving surgical precision and clinical outcomes. They also explore additional benefits of these technologies and consider future innovations that could further advance surgeon's well-being and performance, as well as patient outcomes. To hear more about this topic, make sure to listen the other two podcasts in this series. Independent medical education supported by Alcon and Zeiss.

In this ESCRS IME podcast on the Digital Operating Room (DOR), Drs. Kjell Gunnar Gundersen and Wolfgang Mayer explore the challenges of transitioning to digital operating rooms. They share strategies for integrating digital technology into existing cataract surgical workflows, discuss key considerations for planning and selecting DOR solutions, and outline how to conduct a cost-benefit analysis from both surgeons' and patients' perspectives. Additionally, they examine the impact of digital technologies and advanced robotics on patient outcomes. To hear more about this topic, make sure to listen the other two podcasts in this series. Independent medical education supported by Alcon and Zeiss.

Taking the Next Step as an HR Executive   When CHROs look to advance their career, there are more options available to them than ever before. While it is more common for CHROs to progress to company boards or CEO positions, another path exists in the provider space. The nature of the consultancy and executive search business has changed and experienced HR leaders have insights that allow them to meet these needs. But what does it look like for a CHRO to make this change and where would they begin?   Jeff Bettinger, Chief Administrative Officer at Hudson RPO, has first-hand experience making this change. He has worked in the practitioner space for many years at companies like PetCo, USAA, and Alcon. On this episode of the HRO Today Educational Podcast, Jeff sits down with HRO Today CEO Elliot Clark to share his story about how he moved from the practitioner side of HR to the provider space.   Listen in as Jeff and Elliot explore Jeff's history including his love of Talent Acquisition and discuss how other CHROs and high-level HR decision-makers can begin planning the next phases of their careers. 

JOSEPH N. COHEN is a media investment banker and film financier who founded American Entertainment Investors, AEI, which has advised independent production companies including Alcon, known for THE BLIND SIDE, River Road (12 YEARS A SLAVE) and Black Label (SICARIO). Earlier, he held senior positions at Salomon Bros. and Lehman Brothers before becoming president of Largo Entertainment, with hits including POINT BREAK and MALCOLM X. With over 20 producing credits include WORDS AND PICTURES and KANDAHAR, he is also the author of “Investing in Movies.”                          Host Jason E. Squire is Editor of The Movie Business Book and Professor Emeritus, USC School of Cinematic Arts. Music: “The Day it All Began and it All Ended” by Pawel Feszczuk (License: CC by 4.0).

Join us as we dissect the most compelling charts in the world: from Bitcoin's potential breakout to biotech's resurgence and the shifting landscape of global markets. We dive deep into market trends, exploring the "degenerate economy," AI's impact on various sectors, and why some stocks fly under the radar despite impressive performance. — This episode is brought to you by Stocktoberfest. Join us for a 2-day palooza in Coronado, CA: Get actionable insights on the latest investing trends. Learn about the hottest trends in alternative data products. Network with industry thought leaders: https://stocktoberfest.stocktwits.com/  — Skip Ahead:  (00:00) Introduction and Stocktoberfest (03:35) Bitcoin's long-term chart analysis (13:48) Politics influence on Bitcoin (18:00) Eyes on Solana  (22:33) AI apps (25:07) Biotech's breakout (31:52) NYSW Advance-Decline hitting new ATH's (37:30) Goldman Sachs (39:16) Global market trends (42:52) US vs. Global equities  (48:00) Trends with NO Friends: Spotlight on Alcon ($ALC) (55:45) Apple Intelligence and its potential impact (59:55) $VRT and AI infrastructure companies (01:02:10) Closing thoughts —  Referenced:  • Bill Miller - https://focusdst.com/bill-miller-an-investors-evolution-part-i/ • Caitlin Cook - https://x.com/deadcaitbounce?lang=en • Moonwalk Fitness - https://moonwalk.fit/ • Talkie AI - https://www.talkie-ai.com/ • Alcon - https://investor.alcon.com/stock-information/default.aspx —  Where To Find Howard and Friends:  • Howard - https://stocktwits.com/howardlindzon  • JC - https://stocktwits.com/allstarcharts  • Phil - https://stocktwits.com/ppearlman  • Michael - https://stocktwits.com/MParekh  • Riley - https://stocktwits.com/coloradoriley  • Production and Marketing - https://penname.co/  —  Trends with Friends is brought to you by Stocktwits: https://stocktwits.com/  —  Disclaimer: All opinions expressed on this show are solely the opinions of the hosts' and guests' and do not reflect the opinions of Stocktwits, Inc. or its affiliates. The hosts are not SEC or FINRA registered advisors or professionals. The content of this show is for educational and entertainment purposes only. Please consult with your financial advisor before making any investment decision. Read the full terms & conditions here: https://stocktwits.com/c/uncategorized/2024/02/21/stocktwits-newsletter-disclaimer/

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care. •    Welcome to the Eyeluminaries podcast :05 •    Review of episode 25 :46 •    Bausch + Lomb acquires Trukera Medical 1:32  •    CMS proposes cutting physician payments for fifth straight year 4:09 •    FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 •    FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 •    Intro of Cathleen McCabe, MD 13:07 •    American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 •    In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 •    Besides the two of us, who do you admire in ophthalmology? 23:37 •    Tell us about your work, what you do and how you do it. 27:21 •    Preview of episode 27 33:30 •    Thanks 34:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.

In this episode, Laura Enyedi, MD, and Susan MacDonald, MD, discuss leadership in ophthalmology with Adrienne Graves, as well as her career in pharmaceuticals. ·       Welcome to another episode of Mend the Gap :00 ·       Introduction :27 ·       Welcome Adrienne Graves :39 ·       How did you start in ophthalmology? 1:29 ·       What was your first job and how did you get where you are now? 5:02 ·       How long were you at Alcon? What were your experiences at Alcon? 10:37 ·       Where did you find your mentors? 12:58 ·       Why did you want to turn down the role of CEO at Santen? 15:08 ·       Why did you talk to your mentor about turning down the CEO position? 17:37 ·       How do your experiences shape your mentorship style? 18:42 ·       How to show up professionally 22:51 ·       Speaking up about gender disparities and the value of women in leadership spaces 24:37 ·       Running marathons 26:10 ·       Where does your go-getter attitude come from? 28:36 ·       Being a board member 29:29 ·       Favorite vacation spot? 31:50 ·       Thank you 34:27 We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on Twitter @Healio_OSN. Laura Enyedi, MD, is professor of ophthalmology and pediatrics at Duke Eye Center and medical director of South Durham Ophthalmology in North Carolina. Adrienne Graves is a visionary innovation mentor for the ophthalmic innovation program at Stanford. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Disclosures: The hosts report no relevant financial disclosures. Graves serves on the boards of the American Academy of Ophthalmology (AAO; Emeritus), American Society of Cataract and Refractive Surgeons (ASCRS), Foundation Fighting Blindness (FFB), Glaucoma Research Foundation (GRF), Himalayan Cataract Project, a founding board member of OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders) and Retina Global.

We're chatting with Shaina Steinberg, author of Under the Paper Moon. Join this lively conversation about his work! ABOUT THE AUTHOR: Shaina Steinberg is the author of the Bishop & Gallagher Mysteries, as well as a film and television writer who's worked on Malcolm in the Middle, Everwood, Cold Case, Bionic Woman and Spartacus. Named to the Young and Hungry List in 2013 and the WriteHer List in 2017, she has developed pitches, pilots and features with companies such as Temple Hill, Endgame Entertainment, Fremantle, eOne, Blondie Girl, Josephson Entertainment and Alcon. Most recently, she optioned a feature film to Balcony 9 with shooting scheduled to begin in 2023. She lives with her family in Los Angeles, CA.

Top Stories1. Microsoft CEO leaves Starbucks board⁠Geekwire article⁠2. Seattle startup wins lawsuit against Boeing⁠Seattle Times article⁠3. VC backed biotech Vilya raises $71M⁠Geekwire article⁠4. Lightrail SLU location debateOpinion 1: ⁠The Stranger article⁠Opinion 2: ⁠PSBJ article⁠5. New record store on Vashon⁠Seattle Times article⁠About guest co-host Greg Kunst - Founder & CEO, Aurion Biotech:Greg Kunst founded Aurion Biotech which is a company that develops cell therapies for the treatment of serious eye disorders. He is on the board of Pr3vent, Inc tackling vision health for babies. He's strategic advisor for Oculogica. Prior to this, he held leadership positions at Glockos Corporation and Alcon, both companies tackling eye health.Host Rachel Horgan:Rachel is an independent event producer, emcee and entrepreneur. She worked for the Business Journal for 5 years as their Director of Events interviewing business leaders on stage before launching the weekly podcast. She earned her communication degree from the University of San Diego.Contact:Email: ⁠⁠⁠⁠info@theweeklyseattle.com⁠⁠Instagram: @theweeklyseattleWebsite: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.theweeklyseattle.com

In our latest episode, host Dr. Rob Rothman interviews Greg Kunst, CEO of Aurion Biotech, to delve into the forefront of cell therapy for corneal disease. Join us to discover:Greg's journey from pivotal roles at Alcon and Glaukos to leading Aurion BiotechThe innovative allogenic cell therapy technology developed by AurionHow this technology addresses the global shortage of corneal tissueInsights into the challenges and breakthroughs in scaling production and securing market approvalFuture applications of cell therapy in ophthalmology beyond corneal endothelial diseaseDon't miss this fascinating conversation on the future of medical innovation in ophthalmology! Listen to the episode and subscribe to the OIS Podcast for more updates on the latest trends in eye care and medical technology.

Technology will continue to disrupt the eye care profession. This poses both opportunities and threats for ECPs. In this episode with Travis Beaven, Alcon's Global Vice President of Vision Care Digital Health, we discuss the role technology will play in the future of eye care. A few things we discuss are which technologies will have the greatest impact on the eye care profession, artificial intelligence, adapting to change, privacy issues, and much more! While change and disruption can be unsettling, it also opens the door for innovation and new opportunities that improve the experience for both provider and patient.

U.S. producer prices come in hotter than expected ahead of today's CPI data. Federal Reserve Chairman Jerome Powell says that rates will have to remain elevated for longer. Magnificent 7 stocks help push the Nasdaq to a new record high. Alphabet CEO Sundar Pichai tells CNBC colleagues Stateside that A.I. still has a lot of momentum for the company. U.S. President Joe Biden slaps China with $18bn of new tariffs, targeting EVs, solar cells and steel. We hear exclusively from the U.S. ambassador to the European Union, Mark Gitenstein, who says Biden is sending a clear message to Beijing. And Swiss eyecare group Alcon posts a record profit for the first quarter with CEO David Endicott telling CNBC the company maintains a robust pipeline. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dagny Zhu, MD, Cathleen McCabe, MD, and Susan MacDonald, MD, chat with Jeannette Bankes about leadership in eye care and mentoring the next generation of leaders. ·       Welcome to another episode of Mend the Gap :01 ·       Introduction :23 ·       Welcome Jeannette Bankes 1:11 ·       Tell us about your current role at Alcon. 2:02 ·       Alcon's earnings are outstanding. What do you attribute to? 3:11 ·       Where did your journey start? How did you find your way into ophthalmology? 4:59 ·       What makes a good leader? 10:50 ·       What makes a good mentor? 13:08 ·       How did you become so analytical? 17:07 ·       What are the barriers that you see women in leadership face? 22:44 ·       What are the characteristics of a good mentee? How do you find a mentor? How do you figure out the path you want to pursue? 25:48 ·       How have you balanced your career with your home life? And what is your advice? 28:20 ·       Favorite book? Favorite movie? Stress relief? Vacation spot? 41:05 ·       Thank you 43:30 We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on Twitter @Healio_OSN. Jeannette Bankes is the group president of the global franchises at Alcon. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. Dagny Zhu, MD, is a cornea, cataract, and refractive surgeon and medical director and partner at NVISION Eye Centers in Rowland Heights, CA. She can be reached on twitter @DZEyeMD. Disclosures: The hosts report no relevant financial disclosures. Bankes serves on the board of directors for the ASCRS Foundation.

About Dr. Janelle DavisonDr. Janelle Davison, an award-winning optometrist, graduated from the Pennsylvania College of Optometry at Salus University in 2006. With 18 years of experience in private practice, Dr. Davison is highly respected in the optometric industry. She has received numerous accolades, including being named "The Most Influential Women in Optical for Innovation" by Vision Monday in 2022.As the Founder and owner of Brilliant Eyes, a full-scope primary care vision center in Smyrna, Georgia, Dr. Davison leads a team committed to providing exceptional eye care. She is also the founder of the Visionary Dry Eye Institute of Georgia, a revolutionary referral and co-management center dedicated to advanced dry eye disease services, set to open in spring 2024. Additionally, she co-founded Paradeyem Software, a web-based retail optical solution, where she serves as the Chief Visionary Officer. Paradeyem Software was recognized as a winner of the inaugural 2022 Eyes on Eyecare Innovation Award, securing a grant and grand prize.  Dr. Davison is dedicated to empowering young women of color interested in optometry as a co-founder of S.C.O.R.E., Inc., a non-profit organization.Dr. Davison actively contributes to the optometric community and holds important positions within professional organizations. She serves as an executive board member for the IDOC Alliance group, which consists of over 3000 independent ODs. Additionally, she is a proud member of esteemed associations such as the American Optometric Association, National Optometric Association, and Georgia Optometric Association. Dr. Davison's expertise also extends to her role as a speaker and consultant for Alcon, Tarsus, RVL, and Viatris Pharmaceuticals. Furthermore, she has showcased her knowledge and experience through published articles in various publications including Review Optometric Business, Optometry Times, Optometric Management, Independent Strong, and Modern Optometry.Dr. Davison is an active member of her community serving as an advisory board member for the Cobb County Schools Health and Work-based learning program. For over a decade her vision center has served as an internship location for junior and senior high school students interested in health sciences. Lastly, she is an active member of Alpha Kappa Alpha Sorority, Inc.Beyond her professional achievements, Dr. Davison treasures valuable moments spent with her husband of 18 years and two teenage children.

About Dr. Bollinger Dr. Bollinger is a board-certified optometrist and a Fellow of the American Academy ofOptometry which demonstrates her commitment to excellence and lifelong learning inher profession. She has participated in advisory board meetings & also as a KeyOpinion Leader for companies such as Alcon, Ocular Therapeutix, Novartis, ScienceBased Health, Viatris, and TearScience. She enjoys educating which allows herto share her passion and expertise on dry eye and ocular surgery with other eye careprofessionals and the public. She earned her undergraduate degree in Biology at MiamiUniversity in Ohio and her Doctor of Optometry degree at Ohio State University. Sheserved as an adjunct clinical professor at Ohio State University from 2006-2012. Shehas participated as a clinical investigator in several FDA pharmaceutical and surgicalstudies for dry eye disease, presbyopia, topical steroids, intraocular lenses, andDemodex blepharitis. Her primary career goal is to help patients achieve optimal visionand eye health through personalized and evidence-based care.As an optometrist with 30+ years of experience, she strives to provide exceptional eyecare to patients with various ocular conditions and needs. She has extensiveexperience in perioperative surgical eye care, managing thousands of cases ofrefractive, cataract, and cornea surgeries throughout her career. Dr. Bollinger is alsoskilled in medical eye care, treating patients with glaucoma, diabetes, maculardegeneration, and dry eyes. Helping patients with ocular surface disease, including dryeye, meibomian gland disease, & blepharitis is her primary passion. She currently sees patients at Jacksoneye in Lake Villa, Illinois.

In this episode, Lisa and Ted discuss:What optometrists do and how they help people enhance their quality of life. Essential skills and qualities for those who will have a long and successful optometrist career Understanding the path from high school to graduate school for optometry.The competitive nature of optometry school and the state-specific regulations aspiring optometrists must navigate. Key Takeaways: Optometrists work with all ages, including infants, to catch any vision issues.Ophthalmology and Optometry have different but equally rigorous requirements. Optometrists work closely with Ophthalmologists for advanced eye care needs.Optometry school is very competitive; strong grades in science courses are important. Consider taking sciences outside of just biology, physics, and chemistry beginning in high school if available.Laws regarding what optometrists can do vary by state, so research where your teen may want to practice. Don't rely on your student's advisor to know everything; students should do their own research.  “If you're planning on doing this, do it because you love it. Optometry is not going to make you rich. Medicine is not going to make you rich. There is never a job they will pay you enough to do. It is about doing it because you care about people, and you want to take care of people.” – Ted McElroy, O.D.About Ted McElroy, O.D.: Ted McElroy, OD, founded his practice, Vision Source Tifton, in 1994 in Tifton, GA. In 2004 he served as the Georgia Optometric Association President and in 2016 as President for SECO International. Ted was the recipient of the 1997 GA Optometric Association's (GOA) Young Optometrist of the Year, the 2005 GOA Optometrist of the Year, the 2009 GOA Bernard Kahn Award Recipient, and the 2022 GOA Georgianne Bearden Excellence in Leadership Award.Ted enjoys speaking to optometric students on the joys of private practice and assisting aspiring practice owners. He has served on the Speaker's Bureaus for Alcon, CibaVision, and VSP and is currently on the Speakers Bureau for Vision Source. He is an administrator for Vision Source and serves on the Administrator Advisory Board. Ted is an author published in Invision and Optometric Management, and has also served on the Optometric Management editorial board. He currently serves SECO International as the Chair for the MedPRO 360 committee, the Business Education Program of SECO International. Ted co-hosts the Eyecode Media Podcast with Drs. Chris Wolfe and Aaron Werner.Episode References:#005 Advice for Students Considering Medicine and Healthcare Careers   https://www.flourishcoachingco.com/podcast/5-healthcare-careers/ Get Lisa's Free on-demand video: How-to guide for your teen to choose the right major, college, & career...(without painting themselves into a corner, missing crucial deadlines, or risking choices you both regret). https://flourishcoachingco.com/videoConnect with Ted:Website: https://visionsource-tiftonfamilyeyecare.com/ LinkedIn: https://www.linkedin.com/in/tedmcelroyod/ Connect with Lisa:Website: https://www.flourishcoachingco.com/YouTube: https://www.youtube.com/@flourishcoachingcoInstagram: https://www.instagram.com/flourishcoachingco/LinkedIn: https://www.linkedin.com/company/flourish-coaching-co

Join Paul F. Austin for an interesting weaving of meditation, psychedelics, and conscious leadership, with renowned executive coach Eric Kaufmann. Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-234-eric-kaufmann/ This intimate conversation was recorded live from Eric's “meditation temple” built beside his house in Southern California. Eric shares his journey from being kicked out of college to finding meditation and his early adventures integrating psychedelics into his meditation practice. He reveals his insights from a year-long meditation retreat and emphasizes the growing need to bring humanity and spirituality to business. Eric lays out his two books and their roadmaps to conscious leadership. Finally, the two explore how psychedelics can be integrated into coaching to help leaders transcend “ego myopia,” which Eric sees as the biggest barrier to executive effectiveness and conscious leadership. Eric Kaufmann: Eric Kaufmann combines an unrelenting commitment to results with an unyielding regard for spirit. He is the product of forty years of Zen practice seamlessly woven into three decades of business leadership, both as a corporate leader and advisor to leaders. Eric is an appointed Thought Leader at Harvard's Institute of Coaching. He designed and taught the Coaching for Professionals program at San Diego State University, and has presented at TEDx. Author of The Four Virtues of a Leader and Leadership Breakdown, Eric is laser focused on teaching executives and leaders how to raise their game as human-centered leaders with bottom line accountability. Eric's teaching and guidance to clients such as Dr. Bronner's, Verizon, ASML, Sunpower, Circle, SDG&E, Alcon, and Facebook, weaves in tried-and-true wisdom gleaned from more than 15,000 hours as an executive guide. Eric has lived and worked on three continents, and managed and led at Fortune 100 firms. In addition to his degree in business, he is a certified Clinical Hypnotherapist and Master Scuba diving Instructor. In his previous life, he lived off the grid in a mountain cabin he built by himself. Eric is married for 25 years and is the blessed father of two remarkable young women who know how to navigate the Matrix.   Highlights: Finding spiritual communion through meditation From being kicked out of college to finding meditation Eric's early adventures integrating psychedelics into his meditation practice Revelations from a year-long meditation retreat Turning home and work life into spiritual practices The growing need to bring humanity and spirituality to business Cultivating community outside the workplace How conscious business practices can shape culture Unpacking the four virtues of a leader Transcending ‘Ego Myopia' to conscious leadership Integrating psychedelic experiences through coaching Eric's vision for creating more conscious leaders Learn more about Eric's books   Links: Eric's website: http://www.sagatica.com/ Eric on Instagram: https://www.instagram.com/eric.kaufmann/ Eric on LinkedIn: https://www.linkedin.com/in/erickaufmann7   Episode Sponsors: Neurohacker Collective: Use code THIRDWAVE for an additional 15% off Qualia Senolytic. New Brew's non-alcoholic kratom and kava seltzers. Use code THIRDWAVE25 for 25% off. The Coaching Certification Program by Third Wave's Psychedelic Coaching Institute.

Internal communication helps shape workplace culture, disseminate important information to our organization at scale, and inspire our teams to direct actions. However, its effectiveness is dictated by whether the communication is sent via the proper channel and with the right messaging to land with its audience. In this episode, we hear from the Associate Director of Digital Communications, Design, and User Experience at Alcon, Jessica Griffin. Brought to you by PREZENT.AI and Executive Producer, Rajat Mishra.